Results showed a BRAF V600E missense mutation (c.1799 T > A, variant allele fraction 13.4%), NFE2L2 missense variant (c.101G > A, variant allele fraction 14.9%), microsatellite stable, and tumor mutational burden 3.7 m/MB. This evidence concerns the gene BRAF and neoplasm.